.-The induction of cyclooxygenase is an important event in the pathophysiology of acute lung injury. The purpose of this study was to examine the synergistic effects of various cyclooxygenase products (PGE 2 , PGI 2 , PGF 2␣ ) on thromboxane A 2 (TxA 2 )-mediated pulmonary microvascular dysfunction. The lungs of SpragueDawley rats were perfused ex vivo with Krebs-Henseleit buffer containing indomethacin and PGE 2 (5 ϫ 10 Ϫ8 to 1 ϫ 10 Ϫ7 M), PGF 2␣ (7 ϫ 10 Ϫ9 to 5 ϫ 10 Ϫ6 M), or PGI 2 (5 ϫ 10 Ϫ8 to 2 ϫ 10 Ϫ5 M). The TxA 2 -receptor agonist U-46619 (7 ϫ 10 Ϫ8 M) was then added to the perfusate, and then the capillary filtration coefficient (K f ), pulmonary arterial pressure (Ppa), and total pulmonary vascular resistance (RT) were determined. The K f of lungs perfused with U-46619 was twice that of lungs perfused with buffer alone (P ϭ 0.05). The presence of PGE 2 , PGF 2␣ , and PGI 2 within the perfusate of lungs exposed to U-46619 caused 118, 65, and 68% increases in K f , respectively, over that of lungs perfused with U-46619 alone (P Ͻ 0.03). The RT of lungs perfused with PGE 2 ϩ U-46619 was ϳ30% greater than that of lungs exposed to either U-46619 (P Ͻ 0.02) or PGE 2 (P Ͻ 0.01) alone. When paired measurements of RT taken before and then 15 min after the addition of U-46619 were compared, PGI 2 was found to attenuate U-46619-induced increases in RT (P Ͻ 0.01). These data suggest that PGE 2 , PGI 2 , and PGF 2␣ potentiate the effects of TxA 2 -receptor activation on pulmonary microvascular permeability.
capillary filtration coefficient; pulmonary vascular resistance; isolated perfused lung model THROMBOXANE A 2 (TxA 2 ) has been incriminated as an important mediator of the pulmonary microvascular dysfunction that characterizes tissue ischemia and reperfusion injury (29) , endotoxin exposure (9) , and cutaneous thermal injury (14) . In these conditions, as well as others, TxA 2 has been shown to cause vasoconstriction and enhanced microvascular permeability. Upregulation of cyclooxygenase is an important event in the generation of TxA 2 during acute inflammatory states. Cyclooxygenase catalyzes the incorporation of molecular oxygen into arachidonic acid, yielding a cyclic endoperoxide (PGG 2 ); subsequent peroxidation yields PGH 2 , the precursor for the synthesis of TxA 2 and PGE 2 , PGI 2 , and PGF 2␣ . In general, each of these cyclooxygenase products is released by the lung in response to a particular inflammatory stimulus, albeit in varying amounts (9, 14) .
Despite their common origin, the physiological effects of these substances on the pulmonary microvasculature are diverse. For example, TxA 2 and PGF 2␣ are constrictors of the pulmonary vasculature in rats, whereas PGI 2 is a potent vasodilator (4, 5) . Furthermore, TxA 2 profoundly increases microvascular permeability, whereas the other agents have little, if any, effect by themselves (20, 27) . Several investigators have reported that PGE 2 and PGI 2 potentiate the effects of histamine, bradykinin, and interleukin-1 on microvascular permeability (2, 34, 35) . This observation, as well as the frequency with which PGE 2 and other prostaglandins are released with TxA 2 during acute inflammatory states, led us to postulate that PGE 2 , PGI 2 , and PGF 2␣ potentiate the proinflammatory effects of TxA 2 on the pulmonary microvasculature.
METHODS

Isolated, Perfused Lung Model
Pathogen-free Sprague-Dawley rats (250-350 g) were anesthetized with pentobarbital sodium (40 mg/kg ip). A median sternotomy was performed, and the pulmonary arterial trunk and left atrium were cannulated via the right and left ventricles, respectively. The heart and lungs were excised en bloc, and the lungs were suspended by a ligature from a force transducer (TSD 125C; Biopac Systems, Santa Barbara, CA) for continuous measurement of lung weight. The lungs were perfused with Krebs-Henseleit buffer containing 3% BSA at 0.04 ml · g body wt Ϫ1 ·min Ϫ1 and ventilated with room air at a rate of 60 strokes per minute. The Krebs-Henseleit buffer consists of an aqueous solution containing (in mM) 128 NaCl, 4.7 KCl, 1.2 MgSO 4 , 3.2 CaCl 2 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , and 6.7 dextrose. The perfusate was bubbled with a 95% O 2 -5% CO 2 mixture to maintain a normal pH (7.40-7.5) . Pulmonary arterial pressure (Ppa) and pulmonary venous pressure (Ppv) were continuously measured with pressure transducers (TSD 104A; Biopac Systems) with zero reference at the level of the apex of the lung. These measurements were continuously recorded by a Biopac data acquisition unit (MP100 manager version 3.2.3, hardware version 1.1f, Biopac Systems) interfaced with a personal computer (Dell Computer, Austin, TX). The perfusate was maintained in a 37°C water bath. The first 75 ml of perfusate were discarded to remove blood elements from the vascular space; thereafter, the perfusate was recirculated. The total volume of the recirculating buffer was 70 ml. In each case, the lungs were perfused under zone III conditions with arterial pressure Ͼ venous pressure Ͼ airway pressure. The mean airway pressure was 2-3 mmHg and was maintained below Ppv (3-4 mmHg) by altering the height of the venous reservoir. The lung preparations were isogravimetric immediately before all measurements of pulmonary vascular tone and permeability.
Experimental Protocol
Determination of the effect of indomethacin on U-46619-induced pulmonary microvascular dysfunction. An initial set of experiments (Fig. 1A ) was performed to determine the effect of indomethacin on U-46619-induced changes in pulmonary microvascular function. There were four experimental groups defined by the composition of the perfusate: 1) KrebsHenseleit buffer alone (n ϭ 5), 2) Krebs-Henseleit buffer ϩ U-46619 (n ϭ 7), 3) Krebs-Henseleit buffer ϩ indomethacin (n ϭ 8), and 4) Krebs-Henseleit buffer ϩ indomethacin ϩ U-46619 (n ϭ 6). In this study, indomethacin (100 µM; Sigma Chemical, St. Louis, MO) was added to the perfusate at the beginning of the experiment; 15 min later, U-46619 (7.1 ϫ 10 Ϫ8 M) was added to the perfusate of the appropriate experimental groups. After an additional 15 min of ex vivo perfusion, pulmonary microvascular dysfunction was assessed by measuring the capillary filtration coefficient (K f ), total vascular resistance (RT), and pulmonary vascular pressures as described below.
U-46619 (9,11-dideoxy-11␣,9␣-epoxymethanoprostaglandin F 2␣ ) is a thromboxane-endoperoxide receptor agonist that has been commonly used to mimic the physiological effects of TxA 2 (4, 22, 23, 25) . The concentration of U-46619 was chosen based on a dose-response curve relating increasing concentrations of U-46619 to increases in K f in this experimental system (data not shown). This concentration of U-46619 is associated with increases in K f similar to those seen with in vivo models of acute lung injury (29) . Lastly, the increases in K f associated with U-46619 have been found to be completely inhibited by the thromboxane receptor antagonist SQ-29548 (2 µM; data not shown).
Determination of the effect of PGE 2 and PGF 2␣ on U-46619-induced pulmonary microvascular dysfunction. In these and subsequent experiments (Fig. 1B) , indomethacin (100 µM) was added to the perfusate of the isolated, perfused lung model to inhibit the generation of endogenous prostanoids (3, Fig. 1 . A: experimental protocol study examining effect of indomethacin on U-46619-induced changes in pulmonary microvascular function. Lungs of normal Sprague-Dawley rats (n ϭ 5-8 per experimental group) were harvested and perfused ex vivo with Krebs-Henseleit buffer with or without indomethacin (100 µM). Fifteen minutes later, baseline measurements of pulmonary arterial pressure (Ppa) and pulmonary venous pressure (Ppv) were obtained and U-46619 (7.1 ϫ 10 Ϫ8 M) was added to perfusate. Fifteen minutes later, Ppa, Ppv, and capillary pressure (Pc) were measured, and the capillary filtration coefficient (K f ) and total vascular resistance (RT) were calculated. B: experimental protocol for study examining effect of PGE 2 and PGF 2␣ on U-46619-induced changes in pulmonary microvascular function. Lungs of normal Sprague-Dawley rats (n ϭ 4-8 per experimental group) were harvested and perfused ex vivo with Krebs-Henseleit buffer with 100 µM indomethacin with or without PGE 2 (5 ϫ 10 Ϫ8 M to 1 ϫ 10 Ϫ7 M) or PGF 2␣ (7 ϫ 10 Ϫ9 M to 6 ϫ 10 Ϫ6 M). Fifteen minutes later, baseline measurements of Ppa and Ppv were obtained, and U-46619 (7.1 ϫ 10 Ϫ8 M) was added to perfusate. Fifteen minutes later, Ppa, Ppv, and Pc were measured, and K f and RT were calculated. C: experimental protocol for study examining effect of PGI 2 on U-46619-induced changes in pulmonary microvascular function. Lungs of normal SpragueDawley rats (n ϭ 4-8 per experimental group) were harvested and perfused ex vivo with Krebs-Henseleit buffer containing 100 µM indomethacin for 15 min. PGI 2 (5 ϫ 10 Ϫ8 M to 2 ϫ 10 Ϫ5 M) was added to perfusate, and 1 min later baseline measurements for Ppa and Ppv were obtained. U-46619 (7.1 ϫ 10 Ϫ8 M) was then added to perfusate, and 15 min later Ppa, Ppv, and Pc were measured, and K f and RT were calculated. 5, 37, 38) . This concentration has been previously shown to inhibit the release of TxA 2 , PGF 2␣ , and PGI 2 in an experimental model similar to that employed in these experiments (3, 5) . In this particular study, PGE 2 (Oxford Biomedical Research, Oxford, MI; 1 ϫ 10 Ϫ8 M, 5 ϫ 10 Ϫ8 M, 1 ϫ 10 Ϫ7 M) or PGF 2␣ (Cayman Chemical, Ann Arbor, MI; 7 ϫ 10 Ϫ9 M, 5 ϫ 10 Ϫ7 M, 1 ϫ 10 Ϫ6 M, 5 ϫ 10 Ϫ6 M) was added to the perfusate at the beginning of the experiment; 15 min later, baseline measurements of Ppa and Ppv were obtained. U-46619 (7.1 ϫ 10 Ϫ8 M) was then added to the perfusate and allowed to circulate for 15 min, after which Ppa and Ppv were again measured and the K f and vascular resistance were determined. PGE 2 and PGF 2␣ were prepared in Krebs-Henseleit buffer according to the supplier's recommendations. The concentrations and mode of administration of PGE 2 and PGF 2␣ in these experiments were based on the experience of other investigators utilizing similar experimental models (4, 5, 15, 23, 30, 34) . The addition of these substances to the Krebs-Henseleit buffer had no effect on the pH of the perfusate.
Determination of the effect of PGI 2 on U-46619-induced pulmonary microvascular dysfunction. In this experiment (Fig. 1C) , the ex vivo lung model was perfused with KrebsHenseleit buffer containing indomethacin (100 µM) for 15 min as described above. PGI 2 (Oxford Biomedical Research; 2 ϫ 10 Ϫ8 M, 5 ϫ 10 Ϫ8 M, 2 ϫ 10 Ϫ7 M, 2 ϫ 10 Ϫ6 M, 2 ϫ 10 Ϫ5 M) was then added to the perfusate, and afterward baseline measurements of Ppa and Ppv were obtained. Immediately thereafter, U-46619 (7.1 ϫ 10 Ϫ8 M) was added to the perfusate; 7 min later a second infusion of PGI 2 was given as described above. Seven minutes later (15 min after the addition of U-46619), Ppa and Ppv were measured, and vascular resistance and K f were determined.
The protocol for administering PGI 2 was based on its short half-life at a physiological pH (2-3 min). It was prepared in 50 mM Tris buffer (pH 9.0), as recommended by the supplier, and added to the perfusate immediately following reconstitution. The bioactivity of this preparation was confirmed by its ability to inhibit U-46619-induced vasoconstriction (4). The addition of PGI 2 to the Krebs-Henseleit buffer as described above had no effect on the pH of the perfusate.
Measurement of Pulmonary Microvascular Dysfunction
K f . Pulmonary microvascular permeability was quantitated by determining K f as has been previously described by our laboratory (29) and that of other investigators (11, 39) . Briefly, 15 min after the addition of U-46619, the capillary pressure prior to elevating Ppv (Pc pre ) was measured using the double occlusion technique (1, 28) . Ppv was then elevated 8-10 mmHg by raising the height of the venous reservoir. This results in a two-component weight gain consisting of an initial rapid increase related primarily to recruitment and distension of the vascular bed (minutes 0-1) and a second slow constant weight increase due to fluid filtration across the microvasculature (minutes 1-5). After 5 min of elevated Ppv, Pc was again measured before returning Ppv to baseline (Pc post ). K f was calculated as shown in Eq. 1
where ⌬W is the change in lung weight between minutes 1 and 5 of partial venous outflow occlusion, ⌬T is the duration of elevated Ppv during which ⌬W is measured, and ⌬P is the difference between Pc post and Pc pre . K f is normalized to body weight (expressed as g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 ). This methodology correlates well with the time 0 extrapolation technique (39) .
Pulmonary vascular resistance.
Immediately before the addition of U-46619, Ppa and Ppv were recorded and compared with measurements obtained 15 min after the addition of U-46619. RT was calculated as the total pressure drop across the lung as expressed in Eq. 2
where Q is the flow through the isolated perfused lung. In the isogravimetric state, the pulmonary circulation can be represented as a simple linear model in which Ppa is separated from Pc by a precapillary resistance (arterial resistance, R a ) and Pc is separated from Ppv by a postcapillary resistance (venous resistance, R v ) (1) . Therefore, where RT is determined in the isogravimetric state, R a and R v can be calculated as follows
All resistance calculations (RT, R a , and R v ) were normalized for body weight (expressed as mmHg · ml Ϫ1 ·min Ϫ1 · 100 g body wt Ϫ1 ). RT was also expressed as the absolute difference in determinations of RT obtained before and 15 min after the addition of U-46619 to the ex vivo lung perfusion. This methodology minimizes variability between lung perfusions in that each lung serves as its own control. Furthermore, this methodology allows determination of the effect of each PG on U-46619-induced vasomotor activity after quantitation of the PG's effect on basal vasomotor tone.
In these determinations of K f and vascular resistance, Pc was measured with the double occlusion method as described by Allison et al. (1) and Townsley et al. (28) . This methodology has been demonstrated to correlate closely with measurements of isogravimetric capillary pressure in both normal and acutely injured lungs (1, 28) .
Statistical Analysis
All data are expressed as means Ϯ SE. The sample sizes of the experimental groups ranged from four to eight. The data were compared by ANOVA with a Student-Newman-Keuls test (SigmaStat; Version 2.0; SPSS; Chicago, IL). Statistical significance was considered for a type 1 error of Ͻ5%. All P values represent the results of post hoc comparisons. All experiments were approved by the Committee on the Care and Use of Animals at the University of Texas Southwestern Medical School and Dallas Veterans Affairs Medical Center.
RESULTS
Effect of Indomethacin on Pulmonary Microvascular Function
The K f of lungs exposed to U-46619 in the absence of indomethacin was more than three times greater than that of lungs perfused with Krebs-Henseleit buffer alone ( Fig. 2 ; P Ͻ 0.02). The K f of lungs exposed to U-46619 in the presence of indomethacin (100 µM) was about twice that of lungs perfused with Krebs-Henseleit buffer containing indomethacin but without U-46619 (P ϭ 0.05). The K f of lungs exposed to U-46619 in the presence of indomethacin was ϳ40% less than that of lungs perfused with U-46619 without indomethacin (P Ͻ 0.03). Lesser concentrations of indomethacin (10 µM) did not have this effect in that the K f of lungs exposed to U-46619 in the presence of 10 µM indomethacin was 0.023 Ϯ 0.005 g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 ; this value was not different from that of lungs exposed to U-46619 in the absence of indomethacin, which was 0.019 Ϯ 0.003 g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 . As shown in Fig. 2 , indomethacin (100 µM) did not appear to affect the baseline permeability of the lungs.
Indomethacin also appeared to have important effects on U-46619-induced vasoconstriction. In the absence of indomethacin, U-46619-induced vasoconstriction was evidenced by a 22% (P ϭ 0.04), 36% (P Ͻ 0.01), and 19% (P ϭ 0.01) increase in Ppa, RT, and Pc, respectively, when compared with measurements in lungs perfused with Krebs-Henseleit buffer alone. These data are shown in Table 1 . In the presence of indomethacin, U-46619 caused a 22% increase in Ppa (P Ͻ 0.01) but no significant change in Pc (P ϭ 0.16) or RT (P ϭ 0.1). Furthermore, the RT of lungs perfused with indomethacin ϩ U-46619 was 25% less than that of lungs exposed to U-46619 in the absence of indomethacin (P ϭ 0.01). Indomethacin's effect on U-46619-induced vasoconstriction appeared to be localized primarily to the precapillary location, in that the R a of lungs exposed to indomethacin ϩ U-46619 was ϳ30% less than that of lungs exposed to U-46619 in the absence of indomethacin (P ϭ 0.01). Of interest, the presence of indomethacin (100 µM) within the perfusate did not appear to affect basal pulmonary vasomotor tone in the absence of U-46619.
Effects of Prostaglandins on Pulmonary Microvascular Function
K f . The presence of PGE 2 (5 ϫ 10 Ϫ8 M), PGF 2␣ (5 ϫ 10 Ϫ6 M), or PGI 2 (5 ϫ 10 Ϫ8 M) within the perfusate significantly enhanced the effect of U-46619 on pulmonary microvascular permeability. These data are shown in Fig. 3 . The K f of lungs perfused with U-46619 ϩ PGE 2 , PGF 2␣ , or PGI 2 was 118, 65, and 68% greater, respectively, than that of lungs perfused with U-46619 alone (P Ͻ 0.03). Furthermore, the K f of lungs perfused with U-46619 ϩ PGE 2 , PGF 2␣ , or PGI 2 was 4.4, 2.3, and 2.3 times that of lungs perfused with the respective prostaglandins alone (P Ͻ 0.01). In the absence of U-46619, PGE 2 , PGF 2␣ , and PGI 2 , at the same concentrations as used above, had no effect on pulmonary microvascular permeability.
Concentrations of PGE 2 Ͻ5 ϫ 10 Ϫ8 M had no significant effect on U-46619-induced increases in K f , whereas 1 ϫ 10 Ϫ7 M was associated with an increase in K f similar to that of 5 ϫ 10 Ϫ8 M. The K f of lungs exposed to U-46619 and 1 ϫ 10 Ϫ8 M PGE 2 was not different from that of lungs exposed to U-46619 alone (0.009 Ϯ 0.0004 vs. 0.011 Ϯ 0.001 g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 ; n ϭ 4 and 7, respectively). In contrast, the K f of lungs exposed to U-46619 and either 5 ϫ 10 Ϫ8 M PGE 2 (0.024 Ϯ 0.004 g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 ; n ϭ 6) or 1 ϫ 10 Ϫ7 M PGE 2 (0.0245 Ϯ 0.004 g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 ; n ϭ 4) was significantly greater than that of lungs perfused with U-46619 alone (0.011 Ϯ 0.001 g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 ; n ϭ 7; P Ͻ 0.05) or indomethacin alone (0.006 Ϯ 0.001 g · min Ϫ1 · mmHg Ϫ1 · 100 g body wt Ϫ1 ; n ϭ 8; P Ͻ 0.05). Concentrations of PGF 2␣ Ͻ5 µM (7 ϫ 10 Ϫ9 to 1 ϫ 10 Ϫ6 M) and concentrations of PGI 2 Ͻ5 ϫ 10 Ϫ8 (2 ϫ 10 Ϫ8 M) had no effect on U-46619-induced changes in K f , whereas concentrations Ͼ5 ϫ 10 Ϫ8 M had an effect similar to the latter (data not shown). Fig. 2 . Effect of indomethacin on U-46619-induced changes in pulmonary K f . Lungs of normal Sprague-Dawley rats were perfused ex vivo with Krebs-Henseleit buffer with or without indomethacin (100 µM). Fifteen minutes later, TxA 2 -receptor agonist U-46619 (7.1 ϫ 10 Ϫ8 M) was added to perfusate of half of these lungs. After an additional 15 min, pulmonary microvascular permeability was assessed by measuring K f . *P Ͻ 0.05 vs. lungs perfused without U-46619; # P Ͻ 0.05 vs. lungs perfused with U-46619 but in absence of indomethacin. 
Pulmonary Vascular Pressures and Resistance
The effect of PGE 2 (5 ϫ 10 Ϫ8 M), PGF 2␣ (5 ϫ 10 Ϫ6 M), and PGI 2 (5 ϫ 10 Ϫ8 M) on pulmonary vasomotor tone is shown in Table 2 . In the absence of U-46619, the addition of PGE 2 , PGF 2␣ , or PGI 2 to the perfusate of the ex vivo lung model had no effect on Ppa or Ppv when compared with those lungs perfused with buffer alone. Of interest, the RT of lungs perfused with PGF 2␣ or PGI 2 was significantly greater than that of lungs exposed to Krebs-Henseleit buffer alone (P ϭ 0.01 for both substances). This appeared to be due principally to a 40% greater R a in the lungs exposed to these prostaglandins (P ϭ 0.01). The RT of lungs perfused with PGE 2 was not statistically different from that of lungs perfused with buffer alone (P ϭ 0.057).
The RT of lungs exposed to PGE 2 ϩ U-46619 was significantly greater than that of lungs exposed to U-46619 alone (P Ͻ 0.02). This increase appeared to be due principally to a 49% increase in R a over that of lungs exposed to U-46619 alone (P Ͻ 0.01). In contrast, PGE 2 ϩ U-46619 did not appear to alter either Ppa or Pc when compared with measurements taken in lungs exposed to U-46619 alone. The addition of U-46619 to lungs perfused with PGF 2␣ or PGI 2 did not increase Ppa, Pc, or RT over that associated with the prostaglandin itself or that caused by U-46619 alone. Figure 4 illustrates the effect of PGE 2 , PGF 2␣ , and PGI 2 on U-46619-induced vasoconstriction by comparing the RT of the ex vivo lung model immediately before and 15 min after the addition of U-46619 to the perfusate. In these paired measurements, U-46619 caused a significant increase in RT (P Ͻ 0.05) compared with measurements taken immediately before the addition of U-46619. PGI 2 attenuated the increase in RT associated with U-46619 (P Ͻ 0.01), whereas PGE 2 and PGF 2␣ had no significant effect. Expression of the Ppa data in this manner produced identical results (data not shown).
DISCUSSION
The generation of TxA 2 by the lung during acute inflammatory states is often accompanied by the release of PGE 2 , PGF 2␣ , and PGI 2 (9, 14) . Although synergism between PGE 2 and PGI 2 and various proinflammatory substances such as histamine, bradykinin, and interleukin-1 has been well described (2, 34, 35) , there have been few studies examining the effect of these prostaglandins on TxA 2 -mediated changes in pulmonary microvascular permeability. The data presented in this study suggest the following: 1) PGE 2 , PGF 2␣ , and PGI 2 do not alter microvascular permeability when administered individually into an isolated, buffer-perfused rat lung; 2) each of these prostaglandins potentiates the proinflammatory effects of TxA 2 -receptor activation on pulmonary microvascular permeability; 3) indomethacin (100 µM) attenuates U-46619-induced effects on pulmonary microvascular permeability and vascular resistance; and 4) PGI 2 attenuates TxA 2 -induced vasoconstriction.
Various investigators (12, 20, 21, 27) have examined the individual effects of PGE 2 , PGF 2␣ , and PGI 2 on pulmonary microvascular permeability in normal animal models, including the rat. In contradistinction to Number of lungs their very active role in the regulation of local vasomotor tone, the results of the present study, as well as those of other investigators (20, 21, 27) , suggest that these exogenously administered prostaglandins do not directly alter pulmonary vascular permeability, at least when administered into a buffer-perfused lung model in the concentrations utilized in this study.
To the authors' knowledge, there are no studies examining the effect of PGE 2 and PGF 2␣ on TxA 2 -mediated changes in pulmonary microvascular permeability and only two studies examining the effect of PGI 2 (37, 38) . In the latter two reports (37, 38) , the investigators, utilizing an ex vivo newborn lamb lung model, found that the K f of lungs exposed to PGI 2 and a TxA 2 -receptor agonist (9,11-epithio-11,12-methanoTxA 2 ) was significantly greater than that of lungs exposed to either PGI 2 or TxA 2 -receptor activation alone. This increase in fluid filtration was accompanied by a reduction in vascular hydrostatic pressure, suggesting that, in addition to a direct effect on microvascular permeability, PGI 2 may have increased pulmonary K f by increasing vascular surface area (37, 38) . These results are similar to those of the present study in that the K f of lungs exposed to PGI 2 and U-46619 was nearly 70% greater than that of lungs exposed to U-46619 alone (P Ͻ 0.02). Furthermore, this occurred in a setting in which PGI 2 prevented U-46619-induced vasoconstriction. Of interest in one of the Yoshimura studies (38), PGI 2 alone was found to induce an acute lung injury manifested by ''a diffuse hemorrhagic edema.'' This is clearly different from the experience reported in the present study [as well as that reported by other investigators (12, 21) ] in which PGI 2 alone had no effect on K f . Even in the presence of U-46619, the increase in K f associated with PGI 2 exposure was much more modest than that suggested by Yoshimura et al. (38) . The reason for this difference is unclear, although fundamental differences in the experimental models are likely to be important [e.g., a sanguineous perfusate was utilized in the Yoshimura study (38) , whereas an asanguineous buffer was used in the present study]. Furthermore, the total amount of PGI 2 administered in the Yoshimura study was more than 100 times greater than that of the present study (about 300 µg over 180 min in the Yoshimura study vs. 2.6 µg in the present study).
It is also possible that neutrophils, sequestered within the ex vivo lung model during harvesting, may have contributed to the enhanced microvascular function that characterized exposure of the lungs to U-46619 ϩ PGE 2 or PGF 2␣ . The importance of sequestered neutrophils in the microvascular dysfunction of the ex vivo perfused lung model was initially suggested by Seibert et al. (24) in 1993 in a study in which neutrophils sequestered within the perfused lung were found to contribute significantly to the enhanced permeability associated with pulmonary ischemia-reperfusion injury. One may postulate that in the present study perfusion of the lung with U-46619 [and perhaps PGF 2␣ and PGI 2 (13, 17, 33, 40) ] may have acted on sequestered neutrophils, resulting in the generation of a respiratory burst and, ultimately, a neutrophil-mediated microvascular dysfunction (18, 26) . Other more recent studies have suggested that U-46619, as well as PGE 2 , PGF 2␣ , and PGI 2 , inhibits neutrophil activation, at least as manifested by increases in intracellular free calcium, leukoaggregation, and the release of superoxide radical, ␤-glucuronidase, and leukotriene B 4 (22, 32, 36) . These more recent observations would appear to be inconsistent with the notion that U-46619 or PGE 2 , PGF 2␣ , or PGI 2 increased pulmonary microvascular permeability by activating on neutrophils sequestered within the lung.
Other studies have suggested that activation of the endothelial cell TxA 2 /PGH 2 receptor may directly alter microvascular permeability by changing the endothelial cytoskeletal structure, with resultant changes in cell shape and cell-cell continuity (31). This would suggest a possible second mechanism by which PGF 2␣ and PGI 2 may work through the TxA 2 /PGH 2 receptor to enhance microvascular permeability (13, 17, 33, 40) . Although these studies clearly suggest that PGF 2␣ and PGI 2 may activate the TxA 2 /PGH 2 receptor, the relative affinity of TxA 2 receptors for PGI 2 and PGF 2␣ is extremely low when compared with that of TxA 2 for U-46619 (19, 33, 40) . Furthermore, most of these studies were performed using pharmacological doses in in vitro models. Lastly, PGE 2 has been shown to promote bradykinin-induced edema formation (within the skin), although the mechanism by which this occurs (i.e., whether it is related to neutrophil activation via the EP3 receptor, a direct effect on the microvascular permeability, or an effect of increased blood flow) remains speculative (2, 6, 34, 35) . Furthermore, to the investigators' knowledge, no one has examined the effect of circulating PGE 2 on pulmonary vasomotor tone or permeability in a model similar to that utilized in the present study.
In contrast to the paucity of studies examining the effects of PGE 2 , PGF 2␣ , and PGI 2 on TxA 2 -mediated changes in pulmonary microvascular permeability, there have been numerous studies examining the potential therapeutic effects of prostaglandins, particularly PGE 2 and PGI 2 , on pulmonary microvascular dysfunction (7, 10) . Brigham et al. (7) have shown that the administration of PGE 2 limits endotoxin-induced increases in pulmonary microvascular permeability. In a more recent study, the induction of PGE 2 and PGI 2 release by transfecting a recombinant cyclooxygenase gene into the pulmonary microvasculature was found to attenuate endotoxin-induced vasoconstriction and pulmonary edema (8) , an effect attributed, at least in part, to PGE 2 -and PGI 2 -mediated inhibition of TxA 2 release by the lung itself or inflammatory cells such as neutrophils or platelets sequestered within the lung (8) . If a similar mechanism had been operative in the present study, one would have anticipated a reduction, not increase, in K f . Furthermore, the concentration of TxB 2 (the stable metabolite of TxA 2 ) was measured within the perfusate of several of the lungs exposed to PGE 2 , PGI 2 , and PGF 2␣ and was found to be no different from that of lungs not exposed to these prostaglandins (data not shown).
The addition of indomethacin to the perfusate of the ex vivo lung model appeared to attenuate, but not prevent, U-46619-induced increases in K f . Previous investigators have suggested that indomethacin attenuates increases in pulmonary microvascular permeability by inhibiting the release of proinflammatory prostanoids, particularly TxA 2 , by the lung (16, 39) . In the present study, the addition of U-46619 to the perfusate resulted in a small but statistically significant increase in the release of PGE 2 and TxA 2 by the lung. The presence of 100 µM indomethacin within the perfusate prevented this increase in endogenous PGE 2 and TxA 2 release (data not shown), suggesting that the ''protective'' effect of indomethacin resulted from an inhibition of endogenous prostaglandin and/or TxA 2 release.
In the present study, the RT of lungs perfused with PGI 2 was 40% greater than that of lungs perfused with buffer alone (P ϭ 0.007), whereas PGI 2 totally prevented the increase in vasoconstriction associated with U-46619 exposure. These results are consistent with those of Zhao et al. (40) The results of the present study are consistent with the observations of other investigators who suggested that PGI 2 becomes a more potent vasodilator as the tone of the blood vessel is increased (5) .
Similar to PGI 2 , the RT of lungs perfused with PGF 2␣ was significantly greater than that of lungs perfused with Krebs-Henseleit buffer (P ϭ 0.01), an increase due principally to vasoconstriction of the precapillary segment. This observation is nearly identical to that published by Barnard et al. (5) using a similar experimental model. In contrast to PGI 2 , however, PGF 2␣ had no effect on U-46619-induced vasoconstriction. This is perhaps related to the fact that PGF 2␣ competes less effectively for the TxA 2 /PGH 2 receptor than does U-46619 (5, 17, 25) .
There is very little information available regarding the effect of PGE 2 on pulmonary vasomotor function. In the present study, the RT of lungs perfused with U-46619 ϩ PGE 2 was significantly greater than that of either U-46619 (P Ͻ 0.02) or PGE 2 alone (P Ͻ 0.05), suggesting that PGE 2 potentiated the vasoconstriction associated with U-46619. Enthusiasm for this conclusion is limited by the observations that 1) the Ppa of lungs exposed to PGE 2 ϩ U-46619 was not different from that of lungs exposed to U-46619 alone and 2) the presence of PGE 2 within the perfusate of the lungs did not appear to affect U-46619-induced vasoconstriction when assessed as the absolute change in RT and Ppa in paired measurements taken immediately before and 15 min after the addition of U-46619 (as shown in Fig. 5 ).
In summary, these data are consistent with the hypothesis that PGE 2 , PGI 2 , and PGF 2␣ potentiate the proinflammatory effects of TxA 2 -receptor activation on pulmonary microvascular permeability. Although the increase in pulmonary K f due to PGI 2 ϩ U-46619 may result, in part, from PGI 2 -induced increases in vascular surface area, there is little evidence to support such a mechanism for the increase in K f due to the combined effects of U-46619 ϩ PGE 2 and PGF 2␣ . The synergistic effects of these prostaglandins on TxA 2 -induced pulmonary microvascular dysfunction may contribute to the lung injury that commonly accompanies systemic inflammatory states.
